Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: A register-based national cohort analysis

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 12, 2010, Pages 5258-5265

  Abrahamsen, Bo ^a,b   Eiken, Pia ^c   Eastell, Richard ^d  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c HILLERØD HOSPITAL   (Denmark)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; GLUCOCORTICOID;

AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FEMUR DIAPHYSEAL FRACTURE; FEMUR FRACTURE; FEMUR SUBTROCHANTERIC FRACTURE; FOREARM FRACTURE; HIGH RISK POPULATION; HIP FRACTURE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGISTER; RISK FACTOR;

EID: 78650038476     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-1571     Document Type: Article

References (17)

1. US Food and Drug Administration 2010 Oral bisphosphonates: ongoing safety review of atypical subtrochanteric femur fractures. http://www.fda.gov/Safety/ MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm204127.htm
2. Chapurlat RD, Arlot M, Burt-Pichat B, Chavassieux P, Roux JP, Portero-Muzy N, Delmas PD 2007 Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res 22:1502-1509
3. Stepan JJ, Burr DB, Pavo I, Sipos A, Michalska D, Li J, Fahrleitner-Pammer A, Petto H, Westmore M, Michalsky D, Sato M, Dobnig H 2007 Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone 41:378-385
4. Allen MR, Burr DB 2008 Skeletal microdamage: less about biomechanics and more about remodeling. Clin Rev Bone Miner Metab 6:24-30
5. Ing-Lorenzini K, Desmeules J, Plachta O, Suva D, Dayer P, Peter R 2009 Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf 32:775-785
6. Lee P, van der Wall H, Seibel MJ 2007 Looking beyond low bone mineral density: multiple insufficiency fractures in a woman with post-menopausal osteoporosis on alendronate therapy. J Endocrinol Invest 30:590-597 (Pubitemid 47577812)
7. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG 2008 Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 22:346-350 (Pubitemid 351630250)
8. Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci- Rechtweg C, Cauley J, Leung PC, Boonen S, Santora A, de Papp A, Bauer DC; Fracture Intervention Trial Steering Committee; HORIZON Pivotal Fracture Trial Steering Committee 2010 Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 362:1761-1771
9. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541
10. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR 2006 Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927-2938
11. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077-2082 (Pubitemid 29014065)
12. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822 (Pubitemid 46698462)
13. Abrahamsen B, Eiken P, Eastell R 2009 Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 24:1095-1102
14. Concato J, Shah N, Horwitz RI 2000 Randomized, controlled trials, observational studies, and the hierarchy of research designs.NEngl J Med 342:1887-1892
15. Nieves JW, Bilezikian JP, Lane JM, Einhorn TA, Wang Y, Steinbuch M, Cosman F 2010 Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int 21:399-408
16. Schilcher J, Aspenberg P 2009 Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop 80:413-415
17. Salminen ST, Pihlajamäki HK, Avikainen VJ, Böstman OM 2000 Population based epidemiologic and morphologic study of femoral shaft fractures. Clin Orthop Relat Res 372:241-249